Cargando…

SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has been discussed in the context of Parkinson’s disease (PD) over the last three years. Now that we are entering the long-term phase of this pandemic, we are intrigued to look back and se...

Descripción completa

Detalles Bibliográficos
Autores principales: Boura, Iro, Qamar, Mubasher A., Daddoveri, Francesco, Leta, Valentina, Poplawska-Domaszewicz, Karolina, Falup-Pecurariu, Cristian, Ray Chaudhuri, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526287/
https://www.ncbi.nlm.nih.gov/pubmed/37760965
http://dx.doi.org/10.3390/biomedicines11092524
_version_ 1785110985977102336
author Boura, Iro
Qamar, Mubasher A.
Daddoveri, Francesco
Leta, Valentina
Poplawska-Domaszewicz, Karolina
Falup-Pecurariu, Cristian
Ray Chaudhuri, K.
author_facet Boura, Iro
Qamar, Mubasher A.
Daddoveri, Francesco
Leta, Valentina
Poplawska-Domaszewicz, Karolina
Falup-Pecurariu, Cristian
Ray Chaudhuri, K.
author_sort Boura, Iro
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has been discussed in the context of Parkinson’s disease (PD) over the last three years. Now that we are entering the long-term phase of this pandemic, we are intrigued to look back and see how and why the community of patients with PD was impacted and what knowledge we have collected so far. The relationship between COVID-19 and PD is likely multifactorial in nature. Similar to other systemic infections, a probable worsening of PD symptoms secondary to COVID-19, either transient or persistent (long COVID), has been demonstrated, while the COVID-19-related mortality of PD patients may be increased compared to the general population. These observations could be attributed to direct or indirect damage from SARS-CoV-2 in the central nervous system (CNS) or could result from general infection-related parameters (e.g., hospitalization or drugs) and the sequelae of the COVID-19 pandemic (e.g., quarantine). A growing number of cases of new-onset parkinsonism or PD following SARS-CoV-2 infection have been reported, either closely (post-infectious) or remotely (para-infectious) after a COVID-19 diagnosis, although such a link remains hypothetical. The pathophysiological substrate of these phenomena remains elusive; however, research studies, particularly pathology studies, have suggested various COVID-19-induced degenerative changes with potential associations with PD/parkinsonism. We review the literature to date for answers considering the relationship between SARS-CoV-2 infection and PD/parkinsonism, examining pathophysiology, clinical manifestations, vaccination, and future directions.
format Online
Article
Text
id pubmed-10526287
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105262872023-09-28 SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now Boura, Iro Qamar, Mubasher A. Daddoveri, Francesco Leta, Valentina Poplawska-Domaszewicz, Karolina Falup-Pecurariu, Cristian Ray Chaudhuri, K. Biomedicines Review Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has been discussed in the context of Parkinson’s disease (PD) over the last three years. Now that we are entering the long-term phase of this pandemic, we are intrigued to look back and see how and why the community of patients with PD was impacted and what knowledge we have collected so far. The relationship between COVID-19 and PD is likely multifactorial in nature. Similar to other systemic infections, a probable worsening of PD symptoms secondary to COVID-19, either transient or persistent (long COVID), has been demonstrated, while the COVID-19-related mortality of PD patients may be increased compared to the general population. These observations could be attributed to direct or indirect damage from SARS-CoV-2 in the central nervous system (CNS) or could result from general infection-related parameters (e.g., hospitalization or drugs) and the sequelae of the COVID-19 pandemic (e.g., quarantine). A growing number of cases of new-onset parkinsonism or PD following SARS-CoV-2 infection have been reported, either closely (post-infectious) or remotely (para-infectious) after a COVID-19 diagnosis, although such a link remains hypothetical. The pathophysiological substrate of these phenomena remains elusive; however, research studies, particularly pathology studies, have suggested various COVID-19-induced degenerative changes with potential associations with PD/parkinsonism. We review the literature to date for answers considering the relationship between SARS-CoV-2 infection and PD/parkinsonism, examining pathophysiology, clinical manifestations, vaccination, and future directions. MDPI 2023-09-13 /pmc/articles/PMC10526287/ /pubmed/37760965 http://dx.doi.org/10.3390/biomedicines11092524 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Boura, Iro
Qamar, Mubasher A.
Daddoveri, Francesco
Leta, Valentina
Poplawska-Domaszewicz, Karolina
Falup-Pecurariu, Cristian
Ray Chaudhuri, K.
SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title_full SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title_fullStr SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title_full_unstemmed SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title_short SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
title_sort sars-cov-2 and parkinson’s disease: a review of where we are now
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526287/
https://www.ncbi.nlm.nih.gov/pubmed/37760965
http://dx.doi.org/10.3390/biomedicines11092524
work_keys_str_mv AT bourairo sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT qamarmubashera sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT daddoverifrancesco sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT letavalentina sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT poplawskadomaszewiczkarolina sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT faluppecurariucristian sarscov2andparkinsonsdiseaseareviewofwherewearenow
AT raychaudhurik sarscov2andparkinsonsdiseaseareviewofwherewearenow